Of note, the combination of a CD40 agonistic monoclonal antibody with PD-1 or CTLA-4 inhibition synergistically induced an anti-tumour immune response resulting in tumour regression in another mouse model of PDAC. Here, PDCD1 is linked to neoplasm.